BMO Capital Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $72

Benzinga · 03/11 12:50
BMO Capital analyst Etzer Darout maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $62 to $72.